Cancer drug opdivo qvantig under the microscope: who gets it and how?

This completed study reviewed medical records of 200 adults with cancer who received the drug nivolumab (Opdivo) either as an intravenous infusion or as a subcutaneous injection (Opdivo Qvantig) in community oncology clinics across the United States. The goal was to describe the types of patients receiving each form of the drug, how the treatments are used, and any injection- or infusion-related reactions or infections. This is an observational study, meaning it does not test a new treatment but rather gathers information on current real-world use.